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CHAPTER I 
 
INTRODUCTION 
 
Introduction to pre-clinical molecular imaging 
Molecular imaging is an essential tool to visualize the structure but also the function of 
biological components [1, 2]. It is used both in pre-clinical research on animal models and in 
clinical practice [3]. Endogenous and exogenous molecular contrast agents can be used and 
imaging can be performed at all resolution scales to identify biomarkers, visualize biological 
interactions, or highlight a cellular pathway. In particular, researchers in the area of drug delivery 
need in vivo molecular imaging modalities with a wide array of contrast agents, different 
penetration depths and different resolution scales to study how the drug molecules or carriers 
distribute in the body, the organ or the cell [4, 5]. There is still a need for a low-cost, non-
invasive, three-dimensional molecular imaging technique appropriate for small animal imaging 
at the organ level and allowing multimodal imaging. Current pre-clinical molecular imaging 
techniques are described here to highlight this need.  
Whole body imaging techniques include magnetic resonance imaging (MRI) [6-8], 
computed tomography (CT) [9-11], positron emission tomography (PET) [12-14] and single 
photon emission computed tomography (SPECT) [15, 16]. MRI utilizes varying magnetic fields 
and radiofrequency energy to create contrast between soft tissues, especially water-rich tissues. 
This technique is widely used in pre-clinical research and in the clinic. However, this method 
relies on expensive instrumentation and requires high concentration of exogenous contrast agents 
for molecular imaging [1]. In comparison, CT scanners are also widely available in laboratories 
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and in the clinic and are relatively cost-efficient. CT uses X-rays to probe the sample and images 
are reconstructed in 3D in post-processing. Similarly to MRI, CT also suffers from poor 
sensitivity to molecular contrast agents and high concentrations are thus used. Finally, both PET 
and SPECT use radionuclides to create contrast in the sample and a wide array of contrast agents 
can be used in combination with those two methods. However, cost and availability are an issue 
for both technologies, and even though they are used in the clinic, factors such as the presence of 
radiation or the need for a particle accelerator impede on PET and SPECT usage for pre-clinical 
research. Additionally CT, PET and SPECT all require the use of ionizing radiation.  
In between whole body techniques and microscopy, ultrasound based techniques occupy 
an intermediate position with superior resolution (<100 μm) to whole-body techniques but 
inferior penetration depth (~10 cm). Basic ultrasound imaging [17-19] uses a transducer to send 
and receive sound waves (1-20 MHz) in the body. The sound waves are reflected by different 
structures in the sample and by measuring how long it takes the signal to return to the transducer 
the distance from the transducer to the sample structures can be calculated. Ultrasound 
transducers are commercially available and low-cost, which facilitate their uses in pre-clinical 
research and in the clinic. However, few molecular contrast agents (microbubbles) are available, 
which severely limits the uses of this technology for molecular imaging [1]. Another ultrasound 
based method, photoacoustic imaging [20, 21], uses a pulsed laser to heat absorbers present in 
the sample, and through the photoacoustic effect transforms the local thermal expansion into 
acoustic waves. The acoustic waves are then detected by an ultrasound transducer. Photoacoustic 
images are of similar resolution and can be acquired at similar depths as ultrasound imaging. For 
the photoacoustic effect to take place, a contrast agent that absorbs light and transforms it into 
heat is necessary. Endogenous agents, such as blood [22] and melanin [23], can be visualized 
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with photoacoustic imaging, but a large array of functionalized exogenous contrast agents can 
also be used for molecular imaging. At this time photoacoustic imaging is only used in pre-
clinical research. One of the limitations of both ultrasound-based methods is the requirement for 
the ultrasound transducer to be in contact with the sample, which can complicate the imaging 
procedure in itself, but also makes multimodal imaging difficult. This is an obstacle for eye 
imaging, where current researchers are unlikely to adopt an ultrasound-based method.  
Optical methods are also important in pre-clinical molecular imaging as they are non-
invasive, without ionizing radiations and inexpensive in comparison with whole body 
techniques. A large array of fluorophores and similar contrast agents has also been developed for 
those methods. Fluorescence microscopy is the most commonly used technique to achieve high 
resolution images, with a large selection of exogenous and endogenous contrast agents [24, 25]. 
However, it is limited by its imaging depth (< 200 μm) and field-of-view (requires mosaic past 
~10mm
2
), and it is most commonly used in vitro and ex vivo. On a different scale, 
bioluminescence imaging [26, 27] can be used on large field-of-views (>30 cm
2
) with low 
resolution and traditionally no depth information (new systems now allow 3D imaging [28]). 
However, most in vivo applications of bioluminescence require animals with genetically encoded 
luciferase, which limits the use of this imaging technology in the clinic.   
Contrast-enhanced optical coherence tomography 
There is still a need for a low-cost, non-invasive, three-dimensional molecular imaging 
technique appropriate for small animals at the organ and intra-organ level and allowing 
multimodal imaging. The affordable cost is important for the technology to be accessible at the 
pre-clinical level and in the clinic. A non-invasive imaging technique allows for longitudinal 
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studies on the same animal cohort and cause minimal disturbance to the model being imaged. 
Both of those requirements will contribute to bridging the gap currently seen between results 
obtained in vitro and ex vivo and results obtained in human patients. Three dimensional imaging 
with a large field-of-view and high resolution provides an opportunity to study heterogeneous 
distribution at the organ level. Researchers in the area of drug delivery, for example, aim for the 
homogeneous distribution of their new drug or drug carrier inside a target organ or tissue. Three 
dimensional imaging is also important for retinal imaging, since the retina is composed of many 
distinct layers across its thickness. Finally, multimodal imaging creates a more complete picture 
of the sample by allowing simultaneous imaging of tissue structure, vasculature and the 
molecular target. This is particularly important in drug delivery studies where the target of 
interest is delivered to the tissue through the vasculature, and all three components (tissue, blood 
vessel, drug) can be imaged at once. A technology based on optical coherence tomography 
(OCT) could fulfill those requirements if an appropriate contrast mechanism is identified 
OCT is an optical method that uses near-infrared low coherence light to image tissue 
structure in three dimensions [29, 30]. Using a similar concept to ultrasound, a pulse of light is 
sent into the sample and backscattered at a certain location in the tissue before going back to the 
detector. Each pulse of light is split in between two paths of equal length: the reference arm 
containing a mirror and the sample arm containing the sample that is being imaged. 
Interferometry is used to calculate the difference in path between photons that were 
backscattered in the sample and photons that went down a reference arm with a mirror. OCT 
offers high contrast between tissue structures of different index of refraction. It has become the 
standard of care in retinal imaging in the clinic [31] and is frequently used in pre-clinical 
research to image the eye [32], the skin [33], the brain [34], blood vessel walls [35], and tumor 
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xenografts [36]. In addition to tissue structure, OCT can provide information on blood vessel 
location [37], blood velocity [38] and collagen structure [39]. However, OCT in its traditional 
form is not a good candidate for molecular imaging as the source of contrast in OCT is scattering 
and change in index of refraction. Contrast agents can be used to change tissue attenuation, but 
their detection is non-specific and is not appropriate for high scattering environments such as 
tumors and lesions on the retina. Multiple techniques have been proposed to enable molecular 
imaging in OCT. 
Spectroscopic OCT (SOCT) [40] detects the presence of a contrast agent by analyzing the 
absorption spectra of the tissue as it is illuminated by the broadband OCT source. Contrast agents 
such as melanin [41], Hb/HbO2 [42], some commercially available near infra-red dyes [41], gold 
nanorods [43] and gold nanocages [44] have all been used for SOCT, which thus has the 
potential for molecular imaging. SOCT also has the advantage of being low-cost and to require 
no other equipment than a commercial OCT system. However, SOCT provides the best results 
when the attenuation profile of the sample is known, which can be impractical for in vivo 
experiments, especially longitudinal studies in animals. Additionally, the absorption peak of the 
contrast agent needs to be in the bandwidth of the OCT source, which will attenuate the signal 
used for imaging. This causes a reduction in imaging depth compared with traditional OCT.  
Magneto-motive OCT (MM-OCT) [45] is an active detection method that causes a 
perturbation in the sample in order to detect the presence of contrast agent. Magnetic 
microparticles are injected in the sample and a variable magnetic field is applied to the sample 
while it is being imaged by an OCT system. Under the effect of the magnetic field, the particles 
oscillate slightly in the sample, which is then detected as a change in phase in the OCT signal. 
MM-OCT has been used to image cells in vitro [45], live tadpoles [46] and rat mammary tumors 
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in vivo [47]. Although MM-OCT can successfully identify the contrast agent location, it is 
limited in its ability to quantify the contrast agent’s concentration. Since the oscillation of the 
magnetic particles depends on the viscoelastic properties of the tissue, a higher signal could be 
produced both by an increase in concentration of the contrast agent or a change in the tissue’s 
elasticity. MM-OCT is also limited in imaging speed since the strongest oscillations can usually 
be observed around 50Hz, and multiple oscillations needs to be acquired for each scan.  
Pump-probe OCT (PP-OCT) [48-50] uses a pulsed laser to excite or bleach a fluorophore 
in the sample. Fluorophore with transient absorption are chosen, i.e. they are excited by the 
pump beam to an excited state where they absorb the OCT light. Fluorophores that have transient 
absorption in the near infra-red are chosen so to overlap with the OCT detector. By collecting 
multiple A-scans at the same position with the pump alternatively on or off, the difference in 
OCT signal is analyzed and the location of the contrast agent is determined. PP-OCT enables in 
vivo molecular imaging but requires an expensive pulsed laser, is limited to a few eligible dyes 
and relies on imaging short-lived excited states which are not always easy to capture.  
Photothermal OCT (PT-OCT) is an additional method that has been developed to achieve 
molecular contrast with OCT. We aim to improve PT-OCT so it addresses the shortcomings of 
other contrast-enhanced OCT methods and constitutes a practical OCT-based molecular imaging 
technique.  
Photothermal optical coherence tomography as a molecular imaging technique 
PT-OCT has steadily been receiving interest since its introduction less than a decade ago 
[51,52]. Its instrumentation is simple, requiring only an additional amplitude-modulated laser to 
be co-localized to the OCT imaging beam. To detect the presence of contrast agent, the 
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amplitude-modulated laser is tuned to the absorption peak of the particle or molecule and 
directed toward the sample. The contrast agent will then absorb the light repeatedly and heat the 
sample locally by a few degrees. The resulting sample expansion and change in index of 
refraction will result in a change in optical path length detected by the OCT system. For most 
samples, the change in temperature will be less than 5°C, which lead to a change in optical path 
length on the order of nanometers. This change in optical path length will cause a change in 
phase in the complex OCT signal. As multiple heating cycles are performed by the amplitude-
modulated photothermal laser, repeated OCT scans are needed at the same sample location over 
time to observe the cyclical change in phase in the OCT signal and determine the position of the 
contrast agent in post-processing.  
PT-OCT has been demonstrated in vitro [53, 54], ex vivo [55, 56] and in vivo [57, 58] on 
a multitude of contrast agents, such as gold nanospheres [52], gold nanoshells [59], gold 
nanorods [57, 58], carbon nanotubes [54], indocyanine green [60, 61] and blood [62, 63]. As 
more nanoparticle designs and functionalization are investigated, it is important to have a 
technology that can image their distribution with high resolution and in 3D in high scattering 
environments. PT-OCT is a low-cost option, as commercial OCT systems can be used and the 
photothermal laser does not need to be pulsed (the amplitude modulation is done with a 
mechanical chopper or an acousto-optics modulator).  It also allows for multimodal imaging with 
most other functional OCT modalities, such as Doppler or speckle variance OCT for blood 
vessels visualization. 
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Instrumentation 
A commercial spectral-domain OCT system can be altered for photothermal imaging (see 
Chapter 2, Figure 2 for diagram). A superluminescent diode imaging laser with λ0=860 nm 
central wavelength and 40 nm bandwidth is used as the OCT imaging beam. The light from the 
SLD is split between the sample and reference arms using a 50:50 fiber coupler. Photothermal 
heating is provided by a wavelength tunable Titanium:Sapphire laser. The wavelength of the PT 
laser is tuned to match the absorption peak of the contrast agent used. The PT laser intensity is 
modulated by an acousto-optic modulator following a square wave with frequency f0=500 Hz. 
The light of the PT laser is combined to the superluminescent diode and sent to the reference and 
sample arms using the 50:50 fiber coupler. A telecentric lens is used to focus the light onto the 
sample (1/e
2
 beam diameter ω0=28 μm in air). The returning light is directed to the spectrometer 
and CCD integrated to the Bioptigen system using a circulator (AC photonics). For a typical scan 
pattern, repeated A-scans are collected at the same sample position over time (M-mode scan, 
Δt=100 μs integration time per A-scan) before moving to another position. Scans are collected 
one B-scan at a time in the sample (100 point-positions per 1mm of B-scan) and multiple B-
scans are collected to form volumes (C-scans). All the raw data is saved to memory before 
starting data processing.  
Signal analysis 
In spectral-domain OCT, the signal from the reference and sample arm interferes before reaching 
a spectrometer and a CCD that acts as a detector. The broadband light is then spatially separated 
based on its wavelength. For data processing, the first step is to re-sample the data so it is linear 
as a function of the wavenumber k instead of being linear in wavelength λ. This is accomplished 
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with linear interpolation and a calibrated lamp spectrum. Digital dispersion compensation is then 
applied to the data (to correct for dispersion mismatch in between the sample and the reference 
arm) [64] then a fixed pattern removal is applied to remove DC signal [65]. A Chirp Z transform 
is then applied to the OCT spectrum to transition from wavenumber to depth as the independent 
variable. From the result of the Chirp Z transform is also obtained the magnitude and phase of 
the signal. From the intensity signal, an OCT image can be reconstructed to show the sample 
structure. However, the phase information is needed to obtain PT-OCT data.  
If contrast agent is present at a specific depth inside the sample the absorption coefficient 
will be much higher than for the surrounding sample and the phase signal at the same depth will 
vary over time at a frequency equal to the amplitude modulation frequency of the photothermal 
laser. The derivative of the phase signal with time δΦ is first taken to center the phase to zero 
and avoid phase wrapping [57].  
 
*
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0 *
0 0
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I z t I z t
z t
I z t I z t
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   
    
   (1) 
A Fourier transform of the phase derivative is taken to go from the time domain to the 
frequency domain. If contrast agent was present at this depth inside the sample, a peak is 
expected on the spectrum at the frequency matching the photothermal laser modulation. The 
height of this peak is taken as the photothermal signal. The average amplitude of the nearby (off-
peak) frequencies is taken as the photothermal noise level. This process takes place at all depth 
and for every lateral position along a B-scan. To display the results, the photothermal noise is 
often subtracted from the photothermal signal.  
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PT-OCT has been demonstrated on a wide variety of contrast agents in vitro, ex vivo and 
in vivo, including in high scattering samples. PT-OCT is particularly sensitive to gold 
nanoparticles, which in turn can be functionalized, injected locally or systemically in animals, 
and used for molecular imaging. PT-OCT is a low-cost, non-invasive imaging technology that 
can provide 3D information on an absorber’s distribution. The instrumentation of PT-OCT can 
also be used without modification to perform traditional OCT or spectral variance OCT, 
providing respectively tissue structure images and vasculature images in addition to the PT-OCT 
images. However, before PT-OCT is routinely used as a molecular imaging technique in pre-
clinical research some problems proper to PT-OCT, such as imaging artifacts, long imaging and 
processing times, and large data files must be solved. A theoretical model of PT-OCT could help 
resolve those problems. This is the purpose of the work presented in this thesis.   
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CHAPTER II 
 
DEPTH-RESOLVED ANALYTICAL MODEL AND CORRECTION ALGORITHM FOR 
PHOTOTHERMAL OPTICAL COHERENCE TOMOGRAPHY 
 
Introduction 
Molecular imaging is widely used in pre-clinical studies, for example in drug discovery 
[5], and to study biological processes [1]. Multiple imaging modalities have been developed for 
in vivo molecular imaging, each on different field-of-view and resolution scales, and each with 
their own advantages and disadvantages. Whole body imaging techniques include magnetic 
resonance imaging (MRI) [8], computed tomography (CT) [10] and positron emission 
tomography (PET). These whole body imaging techniques have no limit on imaging depth, but 
are usually high cost methods, with poor sensitivity to the molecular contrast agent (CT, MRI) 
and/or involve the use of ionizing radiation (CT, PET). Ultrasound and photoacoustic [21] 
imaging have a penetration depth of up to 10 cm and have the advantage of being low cost, with 
equipment already available in the clinic. Ultrasound can image contrast agents such as 
microbubbles [66]  and some nanoparticles [67] while photoacoustic imaging can image 
absorbers such as blood, melanin and a wide array of metallic nanoparticles. However, both 
ultrasound and photoacoustic imaging do not allow simultaneous multi-modality imaging since 
they use an ultrasound transducer, which complicates the coupling of multiple imaging 
techniques in one instrument and can also complicate the coupling of the instrument to the 
subject. Finally, optical techniques are limited to low imaging depths but allow for both large 
field-of-views with low resolution (e.g. whole body bioluminescence imaging [27]) and small 
field-of-views with very high resolution (e.g. fluorescence microscopy [24]).  
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There is a need for an optical molecular imaging technique with a large field-of-view and 
high resolution to fill the gap between microscopy and bioluminescence imaging, and 
complement non-optical techniques. Photothermal optical coherence tomography (PT-OCT) is 
an emerging technique [51, 52] that would allow the imaging of contrast agents in vivo with a 
field-of-view (>25mm
2), imaging depth (>1mm) and resolution (<15μm transverse) comparable 
to traditional OCT. In PT-OCT, a laser is used to heat the contrast agent embedded in the sample, 
which in turn heats the sample locally, and thus causes an elastic expansion and a change in the 
index of refraction of the medium. This causes a local variation in optical path length that is then 
detected by a phase-sensitive OCT system. PT-OCT thus offers similar sources of contrast as 
photoacoustic imaging, while allowing multiplexing with other functional OCT modalities (such 
as speckle variance OCT [58]). Additionally this method does not require the instrument to be in 
contact with the sample.  
PT-OCT has been demonstrated in vitro [52], ex vivo [55] and in vivo [57] on a multitude 
of contrast agents, such as gold nanospheres [52], gold nanoshells [55, 68], gold nanorods [53, 
56-58], carbon nanotubes [54], indocyanine green [60, 61] and blood [62, 63]. However, PT-
OCT images are still affected by two artifacts: phase-accumulation (signal becoming brighter 
with depth) and shadowing below high intensity regions. A method has been proposed to correct 
those artifacts [69], but by taking a derivative of the PT-OCT signal this method also drastically 
decreases the signal-to-noise ratio of the image.   
A theoretical model of PT-OCT would allow for a better understanding of the 
photothermal signal, give indications on how to optimize the imaging procedure, and would be a 
tool toward solving the problem of phase accumulation and shadowing. Separate components of 
the photothermal process have been modeled in the past, including the sample heating through 
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the bio-heat conduction equation [57], the change in optical path length due to the change in 
temperature [69], the reflectivity of a sample with specific optical characteristics [70] and the 
phase sensitivity as a function of the signal-to-noise ratio in OCT [71].  
We propose a model that assembles those individual components and includes the 
evolution of the photothermal signal with depth. This is the first model to replicate reliably a PT-
OCT A-scan for a homogenous sample and for a layered heterogeneous sample. This model can 
be customized to the specific instrument (spectral-domain or swept-source OCT), imaging 
parameters, and sample characteristics. Furthermore, we have used the model to implement a 
variation of the CLEAN algorithm [72] which successfully eliminated the effect of phase 
accumulation and shadowing in phantom images and in images of heterogeneous tumors 
acquired in vivo. This paper will present the equations necessary to implement this analytical 
model of PT-OCT and our version of the CLEAN algorithm. Experimental validations in 
phantoms will also be presented in each section. 
Theory 
Model of photothermal signal generation 
PT-OCT relies on photothermal heating of contrast agents by a laser illumination source. 
For the contrast agent to be heated, the photothermal laser light must first reach the contrast 
agent. The photothermal laser power P(z) was generated using a Monte Carlo simulation [73] 
that took into the absorption and scattering coefficient of the sample, respectively μa and μs    
(cm
-1) and z (μm), the distance travelled within the sample. Once the power that reaches the 
contrast agent is known (and the laser spot size is known), we can calculate how much heat will 
be emitted. The bio-heat conduction equation is used to model how the temperature will vary in 
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the sample surrounding the contrast agent when it is illuminated. The bio-heat conduction 
equation with a heat source is the following [57]: 
2aT T
t c




  

     (2) 
where T (K) is the temperature, t (s) is the time, φ (W/m2) is the photothermal laser fluence rate, 
ρ (kg/m3) is the density of the sample, c (J/kg*K) is the specific heat of the sample and α (m2/s) 
is the thermal diffusivity of the sample (α = k/ρc where k (W/m*K) is the thermal conductivity of 
the medium). In the case where the laser spot size is small compared to the absorption depth, 
radial heat transfer dominates the heat conduction equation, which can then be solved in 
cylindrical coordinates. The temperature ΔT at the center of the laser beam (r = 0) will rise and 
fall over one modulation period (2tL) of the photothermal laser in the following way [57]: 
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where tL (s) is the dwell time of the photothermal laser on the sample before an acousto-optic 
modulator reduces the laser power to zero (square waves modulation, 50% duty cycle) and 
 
2
0 0
( ) 1z z z    is the 1/e
2
 beam radius (ω0 (μm) is the waist size inside the tissue estimated 
with a Monte Carlo simulation [74] and z0 (μm) is the Rayleigh range of the objective). The 
change in temperature will cause the sample to undergo two changes: elastic expansion and 
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change in index of refraction. Combined, these phenomena will cause a change in the optical 
path length (ΔOPL) detected by the OCT system. The change in OPL over a set amount of time 
(Δt) at each depth z can be calculated as follows [69]: 
 
0 0 0 0
0
( ) ( ) 1 ( )
z
T T T
dn
OPL z OPL OPL n T T T n T dZ
dT

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  
   (5) 
where T0 (K) is the initial sample temperature, n is the index of refraction, dn/dT (K
-1
) is the 
thermo-optic coefficient that is assumed to be constant for this model and β (K-1) is the thermal 
expansion coefficient of the sample. In our sample, dn/dT>0 and β<0 thus both effects act against 
each other. Over multiple photothermal excitation cycles, the variation in OPL will cause a 
change in phase ΔΦ (mrad) in the OCT signal, which will be detected by our instrument [71]: 
0
4 ( )
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n OPL z
z



        (6) 
where λ0 (nm) is the center wavelength of the OCT laser and the average index of refraction for 
the sample n = n(T0) is used. 
Model of photothermal signal detection 
Once the photothermal signal is generated inside a sample, the signal is detected using an 
OCT system. The signal I(z), collected from one A-scan with a sub-resolution change in reflector 
position ΔΦ(z), is calculated as [71]: 
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    (7) 
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where δ (A/W) is the detector responsivity, e (C) is the electronic charge, S (W) is the power of 
the OCT laser source at the sample, Δt (μs) is the time to acquire one A-scan, Rs(z) is the 
reflectivity at the sample as a function of depth inside the sample, and RR is the reflectivity of the 
reference arm. The sinc function accounts for the spectrometer fall-off with depth, and the 
scaling constant a is determined experimentally. We use the following equation to calculate the 
reflectivity of the sample arm Rs(z) [70]: 
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where μb (cm
-1
) is the backscattering coefficient of the sample, Lc (μm) is the coherence length of 
the OCT laser and f (μm) is the focal position of the OCT beam. Reflectivity models specific for 
phase-sensitive detection [70, 71] were chosen over other models [75], because PT-OCT is a 
phase-sensitive technique 
The experimental signal also contains additive, uncorrelated Gaussian white noise, 
divided here into shot noise Ashot(z)
 
[71]
 
and environmental noise Aenv(z): 
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where φrand and φ’rand are uniformly distributed random phases between -π and π and A0 is an 
experimentally determined magnitude that includes other sources of noise (electronic, 
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vibrational, thermal, etc.). The experimental phase change ΔΦexp(z) is then calculated as the 
phase of the signal and noise terms added together. 
 
 exp ( ) ( ) ( ) ( )shot envz I z A z A z        (11) 
The experimental phase change ΔΦexp(z,t) is acquired over time (in practice 1000 
repeated A-scans at the same location inside a sample), then a Fourier transform is used to go 
from the time domain to the frequency domain.  
 exp
( , ) ( ( , ))p z f FT z t 
     (12) 
The photothermal signal is then defined as the magnitude of the signal at the laser 
modulation frequency f0=500Hz, The photothermal signal is also weighted by the OCT laser 
wavelength λ, the average index of refraction n and the laser modulation frequency f0 in order to 
have units of nm (same as ΔOPL). (See [57] for full derivation).  
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The photothermal noise is calculated following the same equation but where p(z,f0) is 
replaced by the mean magnitude of nearby frequencies.  
Model for heterogeneous samples 
The model described in the previous sections is only valid for homogenous samples. 
However, quasi-heterogeneous samples can be created by superposing layers of different 
homogenous samples. First the power P(z) is simulated for a multi-layer sample using the Monte 
Carlo method [73]. Then the temperature change ΔT and reflectivity Rs(z) are calculated for each 
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layer separately and combined as one continuous function vs depth. The beam waist ω(z) is again 
estimated using a Monte Carlo simulation of a focused Gaussian beam in a multi-layered sample 
[74]. The following calculation steps to obtain the PT-OCT signal are then the same as in the 
one-layer case.  
PT-CLEAN algorithm to eliminate phase accumulation and shadowing 
The CLEAN algorithm was invented in the 1970s with applications in radio astronomy 
[76] before being adapted for microwave imaging [77].  It was then adapted for OCT to reduce 
speckle noise, cancel coherent artifacts and improve resolution [72, 78]. The CLEAN algorithm 
relies on a basic procedure: deconstruct an image point-by-point using the point-spread function 
(PSF) proper to the instrument, then re-construct the image point-by-point using a modified PSF 
to improve image quality. In the case of PT-OCT, we want to correct for phase accumulation and 
shadowing, thus a PSF without those two artifacts will be used for reconstruction.  
First, our analytical model of PT-OCT is used to create the PSF of our system. Using the 
theoretical model for this step is more practical than to image a thin, homogeneous absorber (<10 
μm) that could be approximated as a point. For the PSF, a 7 μm thick absorbing and scattering 
layer of tissue (thickness on the order of the OCT axial resolution) is simulated and serves as a 
1D PSF of PT-OCT, denoted h(z). This PSF can be generated with approximated values for the 
scattering and absorption coefficients since it will be normalized in the next step of the 
algorithm. Second, the original experimental PT-OCT B-scan is considered, and the first pixel in 
depth to have a photothermal signal above a certain threshold (ΔOPL = 2 nm) is selected 
(coordinates [x
(1)
, z
(1)
]). Third, the following deconvolution kernel is subtracted from the original 
image [72]: 
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(1) (1) (1)
max, /imageh z z D x z h            (14) 
where ε<1 is the loop gain, or fraction of the image that is removed at each iteration of the 
algorithm, h[z-z
(1)
] is the PT-OCT PSF centered at [x
(1)
, z
(1)
], Dimage[x
(1)
, z
(1)
] is the intensity of 
the selected pixel in the original PT-OCT B-scan and hmax is the maximum value of the PSF. A 
point of intensity δ[x(1), z(1)] = ε∙Dimage[x
(1)
, z
(1)
] at position [x
(1)
, z
(1)
] is then saved for the final 
image reconstruction.  
The next iteration then starts by finding the first pixel in depth to have a photothermal 
signal above threshold in the remaining image (original image minus deconvolution kernel): 
 
(1) (1) (1)
max, /image imageD h z z D x z h             (15) 
then we proceed as described for the previous iteration. The iterative process is stopped when the 
brightest pixel is below the noise floor of the original image. The final CLEANed image is 
obtained by convoluting each points δ[x(i), z(i)] with a Gaussian function of 7 μm in width at half 
maximum. What is left of Dimage after the iterative process can be added to the CLEANed image 
to provide a realistic-looking noise floor. The PT-CLEAN algorithm takes into account the 
decreasing SNR of the image with depth since the PSF also has a decreasing SNR with depth. 
Additionally, a speckle-correction algorithm can be used if necessary in combination with the 
PT-CLEAN algorithm to improve data visualization. 
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A summary of the PT-CLEAN algorithm can be seen in Fig.1. 
Methods and instrumentation 
Instrumentation 
A commercial spectral-domain OCT system (Bioptigen, Inc.) was altered for 
photothermal imaging (Fig. 2). A superluminescent diode imaging laser (SLD, Fig. 2) with 
λ0=860 nm central wavelength and 40 nm bandwidth (Superlum) was used as the OCT imaging 
beam. The light from the SLD was split between the sample and reference arms using a 50:50 
fiber coupler (50:50, Fig. 2). Photothermal heating was provided by a wavelength tunable 
Titanium:Sapphire laser (Coherent). The wavelength of the PT laser was tuned to match the 
absorption peak of the contrast agent used (λPT=750 nm for indocyanine green and brown human 
Fig.1. Flow diagram of the PT-CLEAN algorithm to remove phase accumulation and 
shadowing. A point spread function is created using the analytical model. The first pixel in 
depth with a PT-OCT signal above threshold is then selected to calculate the deconvolution 
kernel. Two new images are created; a B-scan from which the deconvolution kernel was 
subtracted and a new image where the selected pixel is recorded. The final image is 
reconstructed by convoluting each of the individual saved pixels to a 1-D Gaussian along 
the depth dimension.   
21 
 
hair, λPT=740 nm for gold nanorods). The PT laser intensity was modulated by an acousto-optic 
modulator (Brimrose) (AOM, Fig. 2) following a square wave with frequency f0=500 Hz. The 
light of the PT laser was combined to the superluminescent diode and sent to the reference and 
sample arms using the 50:50 fiber coupler. A  telecentric lens (Bioptigen) was used to focus the 
light onto the sample (1/e
2
 beam diameter ω0=28 μm in air, 36 μm simulated in tissue). The 
returning light was directed to the spectrometer and the CCD integrated to the Bioptigen system 
using a circulator (AC photonics).  
 
Phantom fabrication 
Clear silicone (Quantum Silicones) was used to create solid homogeneous phantoms. The 
silicone consists of two parts (base and curing agent) that need to be mixed in a 10:1 ratio. For all 
phantoms, rutile titanium dioxide (TiO2, <5μm, Sigma Aldrich) was first added to the silicone 
base for a final concentration of 2.05mg/g (μs≈50cm
-1
). The base and TiO2 were then mixed for 
two minutes and degassed for two minutes using a planetary centrifugal mixer (Thinky USA). In 
phantoms where indocyanine green (ICG) was added, it was first dissolved into 800 μL of 70% 
Fig. 2 PT-OCT instrumentation. The light from a superluminescent diode (SLD) is 
split between a reference and sample arm using a 50:50 fiber coupler (50:50). The 
photothermal excitation is provided by a Titanium:Sapphire laser (Ti:Sapphire) 
that is amplitude modulated by an acousto-optic modulator (AOM). HWP: Half-
wave plate. PC: Polarization compensation. 
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ethanol then added to the curing agent of the silicone. It was then mixed and degassed for two 
minutes each in the planetary centrifugal mixed (when ICG was not used, this step was skipped). 
Finally, the base and curing agent were mixed together and degassed. This final mixture was 
then poured into a petri-dish and placed under vacuum at 29 inches of Hg for five minutes with 
brief returns to standard pressure every minute.   
To make layered phantoms, the final silicone mixture for each of the layers was poured 
between two glass slides with 115 μm spacers attached on both sides. The layers were then cured 
at 70°C for 12h and superimposed after curing. For single-layer phantom the silicone mixture 
was poured into a petri-dish and then cured following the same procedure.  
A phantom was made using a human brown hair as a thin absorbing layer. A silicone 
mixture was prepared as described above (no ICG). Then, a single hair was attached to both sides 
of the petri-dish so it would form the hypotenuse of a right triangle of known height (petri dish 
depth) and length (petri-dish diameter). The silicone mixture was then poured into the petri-dish, 
covering part of the hair strand. Using trigonometry, it was thus possible to know the depth of 
the hair as it progressively penetrated the silicone. The phantom was then cured. 
Imaging parameters and signal processing for phantom experiments 
For every phantom experiment, the SLD power at the sample was 2 mW, with a 36 μm 
1/e
2
 beam radius at the focus (in silicone). The photothermal laser power at the sample was 
varied in between 2 mW and 16 mW depending on the experiment. For each 1D depth-resolved 
PT-OCT A-scan, 1000 OCT A-scans were recorded over time with every OCT A-scan lasting 
Δt=100 μs. Each OCT-A scan was resampled from a linear wavelength space to a linear 
wavenumber space, then corrected for dispersion and background subtracted [57]. A Chirp-Z 
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transform was used to convert the wavenumber data to depth-resolved data. The phase data at 
each point in depth was then used for the rest of the analysis. The temporal derivative of the 
phase at each point was calculated and a Fourier-transform was taken in the temporal dimension.  
The data was then treated exactly like the data generated by the analytical model (see Eq. 13).  
For each experimental validations of the model, one B-scan (4 mm in length) containing 
400 PT-OCT A-scans was averaged to produce one noise-reduced PT-OCT A-scan and facilitate 
data visualization . The same method was used with the data generated by the model.   
In vivo imaging 
All animal work was approved by the Vanderbilt IACUC committee, and all surgical 
procedures were performed using aseptic techniques. One nude female mouse (Foxn1
nu
/ Foxn1
nu
, 
The Jackson Laboratory) underwent dorsal skinfold surgery to enable imaging of MDA-MB-231 
(human, breast) tumors. Following baseline (pre-injection) PT-OCT imaging (no signal 
detected), gold nanorods (AuNRs) coated with methoxy-terminated poly(ethylene glycol) (PEG) 
were injected (200 μL injection, 9 nM) with a retro-orbital injection. The mouse was imaged 
again 17h post-injection with PT-OCT while under anesthesia (isofluorane mixed with air, 1.5-
2%). The full protocol, including AuNRs synthesis and surgical procedure is described in detail 
in [58]. For this experiment, the photothermal laser was set to λPT=740 nm, with 70 mW of 
power at the sample. The SLD delivered 6.6 mW of power at the sample. B-scans were acquired 
and processed as explained in the previous section.  
Input parameters for the analytical model 
Two different samples were simulated using the PT-OCT theoretical model: a one layer, 
5 mm thick silicone phantom containing TiO2 (2 mg/g) and ICG (0.09 mg/g), and a silicone 
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phantom containing TiO2 (2 mg/g) and a human brown hair. The different variables that were 
used to implement the theoretical model for those two samples can be seen in Table 1.   
Table 1. Input parameters for PT-OCT analytical model 
Optical properties 5mm ICG 
phantom 
Human hair phantom 
Scattering coefficient μs (cm
-1) 50 [46] 
(Silicone) 50 
(Hair) 55 [79] 
Absorption coefficient μa (cm
-1) 11 [80] 
(Silicone) 0.005 [81] 
(Hair) 50 [79] 
PT laser power P0 (mW) 0-16 15 
PT laser wavelength (nm) 750 750 
Back-scattering coefficient μb 
(cm-1) 
1*† 
1*† 
Thermal conductivity k (W/K) 0.18 [81] 0.25 [82] 
Specific heat c (J/kg*K) 1200 [81] 1602 [82] 
Density of medium ρ (kg/m3) 1020 [81] 1100 [82] 
Laser beam radius ω0 (μm) 36 [74] 36 
Rayleigh length z0 (μm) 1000 1000 
Depth of focus zf (μm) 400 400 
Dwell time of PT laser tL (ms) 1 1 
Index of refraction n 1.44 [81] 
(Silicone) 1.44 
(Hair) 1.55 [79] 
Thermo-optic coefficient dn/dT 
(K-1) 
-340 x 10-6 [83] 
-110 x 10-6 [69]* 
Thermal expansion coefficient β 
(K-1) 
275 x 10-6 [81] 
100 x 10-6 [69]* 
OCT wavelength λ0 (nm) 860 860 
OCT power S (mW) 2 2 
OCT coherence length (μm) 15.1 15.1 
Detector responsivity δ (A/W) 0.2 0.2 
A-scan acquisition time Δt (μs) 100 100 
*Approximate value since exact values were not found in the literature. 
†If necessary, the backscattering coefficient can be more precisely determined with published methods [84]. 
 
Results 
Demonstration of the analytical model 
The parameters for a thick silicone phantom containing TiO2 and ICG (Table 1, first 
column) were used to visualize the model output at different steps of the simulation. The first 
behavior illustrated by the model is the change in OPL (Eq. 5) which is a result of the cyclic 
variations in temperature caused by the photothermal laser and contrast agent. Our model 
simulates both the change in OPL at different depths inside the sample (Fig. 3a) and at a fixed 
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depth over time (Fig. 3b). At this step, only the physical change in the sample is simulated. We 
still need to detect the change in OPL using an OCT system. This step is done using Eq.11, 
which calculates the experimental change in phase detected by a realistic OCT system. The 
experimental phase change is shown over time (Fig. 3c) at the same sample location depicted in 
Fig.3b (z=400 μm). A Fourier transform is then performed on the experimental phase change 
signal (Eq. 12, 13) and the PT-OCT signal is taken as the amplitude of the peak at the 
modulation frequency f0=500 Hz.  
Two characteristics of the signal can be observed from Fig. 3a) for ΔOPL and Eq. 6 for 
ΔΦ(z) : phase accumulation and shadowing. Phase accumulation describes the fact that ΔΦ 
Fig. 3 Demonstration of the PT-OCT analytical output signal. (A) The change 
in optical path length produced in the sample by the photothermal effect is 
plotted as a function of depth and at a fixed depth z=400 μm over repeated A-
scans (B).  (C) The change in optical path length is detected as a noisy change 
in phase by the OCT system. The noiseless change in phase is overlaid in 
magenta to guide the eye. (D) A Fourier transform of the phase signal is taken 
to isolate the PT signal and PT noise. 
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increases with depth for a homogenous sample, and thus the photothermal signal will be detected 
as increasing, even though the amount of contrast agent in the sample is constant with depth. 
Experimentally, this causes images to become brighter with depth even though the sample is 
homogeneous. Shadowing designates a region of high intensity in a region of the sample not 
containing any absorbers, simply because it is directly below a high absorbing region. Those two 
phenomena happen because, as seen in Eq. 5, when ΔT≥0, ΔOPL can only increase or remain 
stable with depth. ΔΦ is a function of optical path length which integrates with depth. Since we 
are never cooling the sample below its initial temperature, ΔOPL and ΔΦ can never decrease 
with depth, which causes phase accumulation and shadowing. Both phase accumulation and 
shadowing are detrimental to the image quality of PT-OCT.  
Validation of the analytical model (monolayer) 
A thick, one layer silicone phantom with 90 μg of ICG per gram of silicone was imaged 
to validate the result predicted by the theoretical model (parameters from Table 1, first column). 
The power of the photothermal laser at the sample was varied between 0 mW and 16 mW. The 
resulting average PT-OCT signal can be seen in Fig. 4 for both the analytical model (blue) and 
the experimental validation (red). The two signals overlap throughout the field of view of the 
OCT system, for all powers of the PT laser. In each case, both the experimental and theoretical 
signal initially increases with depth, a result of phase accumulation. However, the signal 
becomes dominated by noise between 500 μm and 600 μm in depth, a result of the low 
reflectivity of the sample. This region in depth shows poor agreement between the theoretical 
signal and the experimental signal. However, this region of poor agreement corresponds to a 
region already dominated by noise (i.e. SNR< 0 dB). Thus, the model will not routinely be used 
to interpret data at these low SNR levels. Contrary to intuition, the noise floor (caused by the 
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shot noise) is situated at 18 nm in PT-OCT signal (see Fig 4d). This is because the noise follows 
a 1/f behavior and happens to have a value of 18 nm at f=500 Hz. When the SNR approaches 0 
dB the PT-OCT signal invariably increases or decreases to reach 18 nm.  
Validation of the analytical model (multi-layer) and PT-OCT imaging depth 
A second experiment was used to investigate the maximum imaging depth of PT-OCT 
and validate the multi-layer model. The silicone phantom containing the human brown hair was 
imaged in such a way that the hair is at a different known depth (between 0 and 450 μm from the 
surface of the phantom to the center of the hair) every B-scan. The hair was considered to be 130 
Fig. 4 Validation of the PT-OCT analytical model over an A-scan in a single layer 
homogeneous sample. The theoretical signal (blue) was generated from the model 
based on the optical properties listed in Table 1 (5mm ICG phantom). The 
experimental signal (red) is the average A-scan obtained experimentally by 
performing PT-OCT on a silicone phantom containing ICG as an absorber. The 
photothermal laser power at the sample was fixed at (A) 5.8 mW, (B) 9.2 mW and 
(C) 14.1 mW to show the behavior of the signal in relation to the noise floor. The 
noise floor can be seen in (D) when the photothermal laser is turned off. NMSE: 
Normalized Mean Square Error.  
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μm in thickness. An A-scan showing the experimental signal (Fig. 5a, red) from a hair at 80 μm 
in depth and the corresponding theoretical signal (Fig. 5a, blue) are shown to validate the multi-
layer analytical model. The model input to generate the analytical signal can be found in Table 1, 
second column.  
To observe how the PT-OCT signal intensity decreases with the absorber depth, results 
from multiple hair depths were compared. For each hair depth, the PT noise was subtracted from 
the PT signal and this resulting signal was averaged over the cross section of the hair. The result 
was then recorded vs the hair depth (see Fig. 5b, red). The same value was generated by the 
analytical model (Fig. 5b, blue). The experimental and theoretical values overlapped for most of 
the hair positions. The normalized mean square error (NMSE = 
2
(:, ) (:, )
1
(:, ) ( (:, ))
xref i x i
xref i mean xref i



) 
was calculated between theoretical and experimental values at matched depth to quantify the 
agreement between the model predictions and the experimental result. (NMSE=0.84, perfect 
agreement when NMSE=1). 
29 
 
We compared the evolution of the PT signal with depth and the evolution of the OCT 
signal intensity with depth (Fig. 5c). For this we measured the average OCT intensity of an area 
of scatterer inside the phantom, progressively choosing areas at greater depths inside the sample. 
By comparing the point where the experimental PT signal and the experimental OCT signal have 
decreased by 50% of their initial value, it was determined that for this specific sample, the PT 
signal had decreased by half at 220 μm inside the sample, while the OCT intensity had decreased 
by half at 355 μm inside the sample. This indicates that PT-OCT has a smaller imaging depth 
than OCT, but of similar order.   
Fig. 5 Validation of the PT-OCT analytical model over an A-scan in a multi-layered 
heterogeneous sample. (A) Theoretical (blue) and experimental (red) A-scan of a 
human brown hair 80 μm deep inside a scattering silicone phantom. (B) Average 
theoretical and experimental photothermal signal for different hair depths. Each hair 
depth was produced by a separate simulation or recorded on a separate B-scan. The 
signal has decreased by 50% when the hair is 220 μm in depth inside the phantom. 
(C) Experimental average OCT intensity for a section of scatterer at different depths 
inside the sample. The signal has decreased by 50% when the scatterers are 355 μm 
in depth inside the phantom. 
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PT-CLEAN algorithm 
To demonstrate the PT-CLEAN algorithm, multi-layered silicone phantoms containing 
only TiO2 (2.05 mg/g) or both TiO2 and ICG were created. First, a thin layer (115 μm) of ICG 
phantom was deposited on top of a thick (>5 mm) phantom containing only TiO2. The sample 
was imaged with 15 mW of PT laser power at the sample and intensity modulated at 500 Hz. A 
single B-scan with 400 A-scans/B-scan was acquired (see Fig. 6a). Some phase accumulation 
can be seen in the absorbing (ICG) layer. A large amount of signal is also present in the non 
absorbing layer from the effect of shadowing. The PT-CLEAN algorithm was applied to the B-
scan with a loop gain of 0.01 and photothermal threshold of 2 nm. Those parameters were chosen 
experimentally to optimize accuracy, run-time and reduce speckle. The resulting B-scan is 
displayed in Fig. 6b. In the PT-CLEAN image, the signal inside the absorbing layer is more 
constant with depth (reduced phase accumulation) and the signal in the scattering layer decreases 
rapidly to the noise floor (reduced shadowing) (the row-averaged mean signal is indicated as the 
solid white line on Fig.6 a-f). The signal peak at the surface of the CLEANed image stems from 
the fact that the first pixels in depth are all chosen first by the PT-CLEAN algorithm before it 
progresses to the rest of the sample. The phantom layer location on each B-scan was determined 
based on the OCT B-scan that was simultaneously acquired. 
To test the robustness of the PT-CLEAN algorithm, a thin layer of phantom with TiO2 
and no ICG was added on top of the sample described previously and imaged with the same 
parameters (see Fig. 6c). The PT-CLEAN algorithm was applied with the same parameters and 
the resulting B-scan can be seen in Fig. 6d. Again, the PT-CLEAN signal is more constant over 
depth in the absorbing layer and close to the noise floor in the scattering layers.  
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An additional test for the PT-CLEAN algorithm is to differentiate between multiple 
concentrations of absorbers. Two thin layers of phantom were made with TiO2 and respectively 
11 μg and 45 μg of ICG per gram of silicone. Both layers were then mounted on top of a thick 
phantom with only TiO2 with the high concentration layer on top (see Fig. 6e). The imaging 
parameters and the PT-CLEAN parameters were the same as for the previous two experiments. 
The PT-CLEAN images can be seen in Fig. 6f. When the absorber concentration goes from high 
Fig. 6 Demonstration of the PT-CLEAN algorithm and comparison to traditional PT-
OCT B-scans. (A) Thin ICG phantom on thick scattering (TiO2) layer and (B) resulting 
B-scan after performing the PT-CLEAN algorithm. The horizontal dashed white lines 
indicate the limit of each layer. The solid white line is the average signal intensity vs. 
depth. (C) Thin ICG layer between a thin and a thick scattering layer and (D) after 
application of the PT-CLEAN algorithm. (E) Layer with a high ICG concentration, 
over a low ICG concentration layer, both over a scattering phantom and (F) after 
application of the PT-CLEAN algorithm. Scale bar: 100 μm. 
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to low with depth (Fig. 6e and f), the traditional PT B-scan displays an increase in signal with 
depth throughout both absorbing layers, which is due to phase accumulation. However, the PT-
CLEAN image shows a decreasing signal with depth that is proportional to the absorption from 
both layers. This shows the advantage of the PT-CLEAN algorithm over the traditional PT-OCT 
processing.  
The PT-CLEAN algorithm was also applied to a true heterogeneous sample: a mouse 
tumor xenograft imaged in vivo using a dorsal window 17h after systemic injection of gold 
nanorods through the tail vein. Both the original PT-OCT B-scan and the PT-CLEANed scan can 
be seen in Figure 7a and b. Phase accumulation and shadowing are shown to be reduced by the 
PT-CLEAN algorithm even in a truly heterogeneous sample. A median filter was also applied to 
the original PT-OCT B-scan (Fig. 7a) and the PT-CLEANed B-scan (Fig. 7b) to demonstrate the 
use of a speckle-correction technique in combination with the PT-CLEAN algorithm.  
Fig. 7 Demonstration of the PT-CLEAN algorithm on in vivo tumor sample. (A) In 
vivo PT-OCT B-scan of a tumor xenograft after retro-orbital injection of gold 
nanorods. Both phase accumulation (boxed area) and shadowing (arrows) are visible. 
(B) B-scan after application of the PT-CLEAN algorithm. Both phase accumulation 
and shadowing are reduced. Scale bar: 500 μm. 
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Discussion 
PT-OCT is an emerging technique for pre-clinical molecular imaging. It has been 
experimentally demonstrated in vitro, ex vivo and in vivo in the past and parts of its signal had 
been modeled. However, this is the first time that a comprehensive, customizable analytical 
model of a PT-OCT A-scan is presented for homogeneous and quasi-heterogeneous samples. We 
have validated our model against experimental data acquired in a homogeneous silicone phantom 
containing TiO2 (scatterer) and ICG (absorber) at various photothermal laser powers, and in a 
multi-layer phantom containing TiO2 and a human hair (absorber). Previous models of PT-OCT 
only described the general shape of the photothermal signal with depth and did not take into 
consideration the effect of noise. Our model is the first to match the data directly instead of being 
mathematically fitted to the experimental data points. Our model can also predict the A-scan 
obtained for different instrument design, imaging parameters, and sample composition.  
By layering different sections of homogeneous samples, a heterogeneous sample was 
approximated. For in vivo drug delivery and molecular imaging experiments, it is expected that 
the contrast agent will diffuse through the sample and form a heterogeneous distribution. As a 
first step toward re-creating this situation, we created a three-layer phantom experiment and 
simulation: two large sections of scattering silicone surrounding a thin layer (130 μm) of 
absorber. A human brown hair was used as the thin absorption layer. This choice of absorber 
allowed us to easily vary the position of the absorbing layer in depth inside the sample and to 
assure that no leaking of the absorber into the scattering layer occurred. We measured the 
photothermal signal as a function of the hair depth and determined that the photothermal signal 
decreases with depth slightly more rapidly than OCT. This experiment also validated our model 
for a multi-layered sample, as the experimental values agreed with the theoretical values 
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(NMSE=0.84). The maximum imaging depth for PT-OCT is strongly dependent on the type of 
sample being imaged, how many absorbing layers it has and where they are located. With our 
analytical model, we can now predict the imaging depth that will be obtained in practice for a 
given sample, which could not be done theoretically before. We can also select imaging 
parameters (e.g. photothermal laser power, photothermal modulation frequency, or the 
integration time of the detector) to maximize the signal strength in a specific sample. In the 
future, this model can be used to simulate a multi-layered sample that is a better approximation 
of a heterogeneous distribution of contrast agents inside a tissue sample.  
Using our analytical model, we were able to simulate the PT-OCT signal from a 
homogeneous 7 μm thick absorber, which would be impractical to do without a model. This 
provided a point-spread function for our PT-OCT system. It was then possible to implement a 
modification of the CLEAN algorithm, which relies on the PSF of an instrument to improve 
image resolution and quality. The PSF should be generated with realistic optical parameters for 
the sample and instrument used to re-create the most accurate PT-OCT image. With the PT-
CLEAN algorithm, we have demonstrated that phase accumulation and shadowing can be 
reduced in different layered samples and in a heterogeneous in vivo tumor sample, which is an 
improvement over traditional photothermal B-scans. Additionally, PT-CLEAN preserves the 
units of change in optical path length proper to PT-OCT and does not require any assumption on 
the signal shape or the sample composition, which allows its application to homogeneous and 
heterogeneous samples. In comparison with an algorithm proposed before [69], PT-CLEAN does 
not assume that the change in optical path length is proportional to the geometrical depth inside 
the medium (as seen in Fig. 3a, ΔOPL levels off with depth). It is therefore appropriate for 
complex, heterogeneous samples, and was thus the first algorithm of its kind to be applied to in 
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vivo PT-OCT B-scans. Axial resolution for PT-OCT used to be difficult to define, since a small 
region of absorber could create a large shadow once the B-scan was processed. With the PT-
CLEAN algorithm, the shadowing is eliminated and the effective axial resolution of PT-OCT is 
improved.  
In conclusion, we have presented and validated the first analytical model of PT-OCT that 
can predict signal intensity with depth in homogeneous and multi-layered samples. We have also 
presented the PT-CLEAN algorithm to reduce phase accumulation and shadowing, effectively 
improving the axial resolution of PT-OCT.    
  
36 
 
CHAPTER III 
 
CONCLUSION AND FUTURE DIRECTIONS 
 
An analytical model of PT-OCT capable of calculating the signal intensity with depth 
was assembled. Theoretical predictions were successfully compared to experimental A-scans 
taken in single- and multi-layered silicone phantoms. A multi-layered phantom containing a 
human hair, acting here as a thin absorbing layer, was used to determine how the PT-OCT and 
OCT signal decreases with depth inside a sample. It was observed that the PT-OCT signal 
decreases slightly more rapidly than the OCT signal. This was predicted by the theoretical model 
and confirmed by experimental data.  
A post-processing algorithm to reduce the effect of phase accumulation and shadowing 
was also proposed and demonstrated on experimental images. The PT-CLEAN algorithm was 
created using a point-spread function generated by the theoretical model, and then tested on thin 
silicone phantoms containing ICG and a mouse tumor xenograft imaged in vivo after injection of 
gold nanorods. The reduction in shadowing observed after the application of PT-CLEAN is 
important, as it effectively increases the axial resolution of PT-OCT.  
The analytical model of PT-OCT will be used in the future to optimize imaging 
parameters for PT-OCT. Since the process of building a new PT-OCT system specifically for in 
vivo studies is underway, the theoretical model of PT-OCT will be used to guide instrumentation 
and imaging parameters choices while taking into consideration the type of tissue that will be 
studied. 
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